## Drug Summary
Tezacaftor is a CFTR corrector, primarily used in the management of cystic fibrosis, a genetic disease marked by faulty chloride and sodium ion transport due to mutations in the CFTR gene, leading to thick mucus secretions affecting the lungs and other organs. Approved by the FDA in 2018, Tezacaftor is most effective in patients with specific CFTR mutations like F508del, either alone or in combination with ivacaftor and elexacaftor. This combination therapy helps address the defective protein folding and function associated with these mutations, thus alleviating symptoms through improved lung function and decreased sweat chloride levels. Tezacaftorâ€™s pharmacokinetic profile reveals significant metabolism predominately via CYP3A4 and CYP3A5 enzymes, with optimal absorption when taken with a high-fat meal.

## Drug Targets, Enzymes, Transporters, and Carriers
Tezacaftor specifically targets the CFTR protein, aiming to correct the misprocessing of F508del, a common mutation in cystic fibrosis. By improving the positioning and function of this protein within the cell membrane, it facilitates more effective chloride and sodium ion passage. The drug undergoes extensive metabolism, primarily through enzymes CYP3A4 and CYP3A5. Moreover, it is notably involved with several enzymes (like CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, and CYP2D6) and transporters including ABCB1 (P-glycoprotein), ABCG2, and various solute carrier family proteins (SLC22A2, SLC22A6, SLC22A8, SLCO1B1, SLCO1B3), which may influence its distribution and excretion.

## Pharmacogenetics
Pharmacogenetics of Tezacaftor is particularly vital because its efficacy is closely tied to the genetic background of cystic fibrosis patients. It is specifically designed to amend the defects caused by the F508del mutation in the CFTR gene, among others responsive to this correction. Variations in the metabolic enzymes, especially CYP3A4 and CYP3A5, could influence the pharmacokinetics of tezacaftor, modifying drug exposure and potentially the adverse effects or efficacy. While no specific pharmacogenetic guidelines are mandated for tezacaftor adjusting based on CYP3A genotypes, the extensive metabolism by these enzymes suggests that genetic variations in these pathways could impact therapeutic outcomes, warranting further investigation and careful clinical monitoring.